Bitcoin prices have stumbled and the alt-currency has some formidable headwinds, so investors are again looking to gold as the traditional flight-to-safety investment. These three gold stocks are more attractive than bitcoin any day.
Articles by Marshall Hargrave
By Marshall Hargrave | Apr 10, 2017
Snapchat and other tech IPOs draw lots of buzz but the buzzy IPOs don't always pay off for the average investor. Here are three overlooked IPOs that may be more attractive.
By Marshall Hargrave | Apr 6, 2017
Companies in our top dividends list this month reflect wide range of businesses. They include a shoe seller, a big name in toothpaste, a cloud-computing company and a toymaker.
By Marshall Hargrave | Mar 23, 2017
Our top organic foods stock is a company with superior returns on invested capital, dividends and a better balance sheet than others in the organic foods business . . . and its name may surprise you.
By Marshall Hargrave | Mar 8, 2017
The Goldman Sachs list of top hedge fund stocks recaps recent favorites from hedge fund billionaires. We've selected three stocks that investors shouldn't miss.
By Marshall Hargrave | Mar 6, 2017
Focusing on companies that consistently raise dividends can really pay off. Here are five companies set to post dividend increases in March.
By Marshall Hargrave | Feb 22, 2017
Flying cars could be plying the skies in as few as three years, and Uber is out front in the emerging industry. These two stocks stand to benefit.
By Marshall Hargrave | Feb 13, 2017
Investors can secure higher gains by seeking out companies with a steady record of stock dividend increases. Here are five companies that are raising their dividends in February.
By Marshall Hargrave | Feb 8, 2017
U.S.-focused companies are a good bet for 2017 with Trump in the White House. Here are three low-risk stocks with attractive yields that may give you some peace of mind for the year ahead.
By Marshall Hargrave | Jan 25, 2017
Look for drug companies that offer superior and transformative drug product. Here are three health care dividend stocks that are well-positioned even if drug regulation changes appear on the horizon.